Breaking News, Promotions & Moves

Avomeen Names David Riggs President

Brings nearly 30 years of advanced analytical chemistry experience to the role

David W. Riggs has been appointed president of Avomeen Analytical Services. Previously, Mr. Riggs served as president of Chemir and Cas-MI, and as executive vice president at Evans Analytical Group. Through his experiences at his previous positions Mr. Riggs brings nearly 30 years of advanced analytical chemistry, innovative product development, chemical engineering and other related analytical and industry experience to this new role.

“David brings excellent credentials into our growing laboratory and his dedication to building successful relationships with clients through long term mutually beneficial business partnerships is to be admired,” said Shri Thanedar, chief executive officer of Avomeen Analytical Services. “He has the vision and ambition to take Avomeen to the next level and comes highly recommended from within the industry. David brings to Avomeen his experience with sales integrations, acquisitions, and the launch of new testing opportunities.”

Mr. Riggs stated, “In recent years Avomeen has seen double and even triple digit growth through their quickly growing reputation as the laboratory to turn to when you need a complex project solved quickly with accurate and reliable results the first time around. I am excited to be joining a rapidly growing team of multi-disciplinary experts and will help to ensure that our clients continue to receive world-class service and solutions to their challenging problems.”

A graduate of Michigan State University with degrees in chemical engineering, Mr. Riggs is well known for his insights both within and outside of the workforce supporting several well-known charitable organizations including the American Red Cross and has received the Turnaround of the Year Award by the T.M.A.


 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters